🔎 Trials Near Me

Utama › Skleroderma Difus › Michigan

Kajian klinikal Skleroderma Difus di Michigan

7 kajian untuk Skleroderma Difus sedang mencari peserta di lokasi di Michigan.

Bandar di Michigan

Teks kajian rasmi (Bahasa Inggeris)

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  • Uni Of Michigan Health System, Ann Arbor
  • Wayne State University, Detroit
  • Clinical Research Inst of MI, Saint Clair Shores
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06470048

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Ann Arbor
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

  • University of Michigan, Ann Arbor
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

  • University of Michigan, Ann Arbor
Mengambil pesertaFasa 2/3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Ann Arbor
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06733935

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  • Galderma Investigational Site # 8743, Ann Arbor
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Mac 2026 · NCT07047690

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

  • University of Michigan, Ann Arbor
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jan 2026 · NCT06675344

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.